Flavia Serpieri
Papers
1
Total Citations
21
H-Index
1
About
Flavia Serpieri is a biotechnologist whose work has advanced the development of therapeutic monoclonal antibodies, particularly in the realm of immunology and protein engineering. Her most-cited research, "Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells" (2010, 21 citations), focuses on optimizing antibody formats for targeting CD3, a key receptor on T cells. This study systematically compares the expression and functional properties of humanized IgG and FvFc anti-CD3 antibodies in Chinese hamster ovary (CHO) cells, a critical step for scalable, cost-effective production of immunotherapies. By demonstrating how antibody architecture influences yield, stability, and binding affinity, Serpieri’s work contributes to the rational design of next-generation biologics for autoimmune diseases and transplant rejection. Her findings underscore the importance of expression system choice in bioprocessing, offering practical insights for both academic researchers and industry scientists. Though her citation count is modest, the specificity and translational relevance of her research highlight her role in bridging fundamental antibody engineering with clinical application.
Research Focus
Key Achievements
Top Papers
- 1